On July 1, 2020, Everest Pharma proudly launched VENTOXEN (Venetoclax 100 mg), the generic version of the FDA-approved VENCLEXTA, marking a major milestone in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). This introduction provided a more affordable, high-quality treatment option for patients battling blood cancers.
To further support patient safety and treatment protocols, VENTOXEN 10 (Venetoclax 10 mg) was subsequently introduced. This lower-strength formulation facilitates the recommended dose ramp-up strategy—starting patients on a low dose and gradually increasing to a full therapeutic dose. The ramp-up period is designed to reduce the risk of tumor lysis syndrome (TLS), a potentially serious complication, while effectively targeting cancer cells.
Venetoclax, marketed under the brand name VENCLEXTA by AbbVie and Genentech, is a BCL-2 inhibitor used in combination with other therapies for the treatment of CLL/SLL and AML. With the introduction of VENTOXEN, Everest Pharma seeks to enhance accessibility to this life-saving therapy—especially in regions where affordability has been a longstanding challenge.
“We are proud to launch VENTOXEN as a high-quality generic alternative to FDA-approved VENCLEXTA,” said Mr. Anwarul Hoq, CEO of Everest Pharma. “This is a significant achievement in our mission to expand access to essential cancer therapies without compromising on efficacy, safety, or quality.”
The availability of VENTOXEN (Generic of VENCLEXTA) is expected to stimulate competition in the oncology market, helping to lower treatment costs and improve patient access to breakthrough medications.
About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.

For more information on VENTOXEN and Everest Pharma’s portfolio, visit https://www.ventoxen.com/ or https://www.everestpharmabd.com/